Next Article in Journal
The Genetic Evidence of Burn-Induced Cardiac Mitochondrial Metabolism Dysfunction
Next Article in Special Issue
Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
Previous Article in Journal
The miRNA Content of Exosomes Released from the Glioma Microenvironment Can Affect Malignant Progression
Previous Article in Special Issue
Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma
Review

The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma

1
Department of Genetics, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 845 05 Bratislava, Slovakia
2
Oncology Outpatient Clinic, Hospital of the Hospitaller Order of Saint John of God, 814 65 Bratislava, Slovakia
3
Department of Tumor Immunology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 845 05 Bratislava, Slovakia
4
2nd Department of Oncology, Faculty of Medicine, Bratislava and National Cancer Institute, Comenius University, 833 10 Bratislava, Slovakia
*
Author to whom correspondence should be addressed.
Biomedicines 2020, 8(12), 565; https://doi.org/10.3390/biomedicines8120565
Received: 9 November 2020 / Revised: 27 November 2020 / Accepted: 2 December 2020 / Published: 3 December 2020
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignant tumors due to the absence of biomarkers for early-stage detection and poor response to therapy. Since mounting evidence supports the role of microbiota composition in tumorigenesis and cancer treatment, the link between microbiome and PDAC has been described. In this review, we summarize the current knowledge regarding the impact of the gut and oral microbiome on the risk of PDAC development. Microenvironment-driven therapy and immune system interactions are also discussed. More importantly, we provide an overview of the clinical trials evaluating the microbiota role in the risk, prognosis, and treatment of patients suffering from PDAC and solid tumors. According to the research findings, immune tolerance might result from the microbiota-derived remodeling of pancreatic tumor microenvironment. Thus, microbiome profiling and targeting represent the potential trend to enhance antitumor immunity and improve the efficacy of PDAC treatment. View Full-Text
Keywords: pancreatic ductal adenocarcinoma (PDAC); pancreatic microbiome; immune suppression; tumor microenvironment; cancer treatment; microbiota modulation pancreatic ductal adenocarcinoma (PDAC); pancreatic microbiome; immune suppression; tumor microenvironment; cancer treatment; microbiota modulation
Show Figures

Graphical abstract

MDPI and ACS Style

Ciernikova, S.; Novisedlakova, M.; Cholujova, D.; Stevurkova, V.; Mego, M. The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma. Biomedicines 2020, 8, 565. https://doi.org/10.3390/biomedicines8120565

AMA Style

Ciernikova S, Novisedlakova M, Cholujova D, Stevurkova V, Mego M. The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma. Biomedicines. 2020; 8(12):565. https://doi.org/10.3390/biomedicines8120565

Chicago/Turabian Style

Ciernikova, Sona, Maria Novisedlakova, Danka Cholujova, Viola Stevurkova, and Michal Mego. 2020. "The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma" Biomedicines 8, no. 12: 565. https://doi.org/10.3390/biomedicines8120565

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop